In patients with intermediate- to high-risk, use of pegfilgrastim biosimilars could optimize management of FN risk. Use of biosimilar pegfilgrastim as a prophylaxis in patients with cancer and a high ...

Lupin has inked an agreement with Valorum for biosimilar Armlupeg, and it has received a tentative OK from the FDA for generic Mayzent.

With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require ...

The FDA has approved pegfilgrastim-unne (Armlupeg) for the treatment of patients with nonmyeloid cancers undergoing treatment with myelosuppressive anticancer drugs linked to a significant chance of ...

Credit: Coherus. The on-body injector includes features such as a retractable needle mechanism, an indicator, status light and auditory signal to help patients confirm the dose has been administered.

New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pegfilgrastim Biosimilars Global Market Report 2023" - https://www ...

Learn everything you need to know about Pegfilgrastim-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...

Two authors (TK, MK) systematically searched electronic databases PubMed, EMBASE and CENTRAL. Databases were searched using a combination of PubMed MeSH terms and relevant search terms for ‘filgrastim ...

The purpose of this phase I/II dose-finding study was to assess the proficiency of megakaryocytic progenitor mobilization with fixed doses of pegfilgrastim in patients with solid tumours receiving ...

Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma Whole-Genome Profiling of Pediatric Diffuse ...